Ultragenyx reported a strong fourth quarter in 2025 with total revenue reaching $207 million, a 25% increase year-over-year. The company also initiated a strategic restructuring plan to reduce expenses and headcount, aiming for profitability in 2027, and highlighted key clinical and regulatory catalysts for 2026.

Ultragenyx delivered 20% revenue growth from its commercial therapies in the first half of the year compared to the prior year, with total revenue reaching $166 million in Q2 2025. The company reaffirmed its 2025 revenue guidance and its path to GAAP profitability in 2027, while advancing key clinical programs like UX143 for osteogenesis imperfecta and GTX-102 for Angelman syndrome.

Ultragenyx reported total revenue of $139 million for the first quarter of 2025, representing 28% growth year-over-year. Net loss improved to $151 million, or $1.57 per share, compared to a net loss of $171 million, or $2.03 per share, in the same period last year. The company reaffirmed its full-year 2025 financial guidance.

Ultragenyx delivered $164,877,000 in revenue for Q4 2024, a 29% YoY increase, primarily fueled by Crysvita and Dojolvi sales. Despite higher revenue, the company reported a net loss of $133,385,000, with increased R&D and operating expenses.

Ultragenyx reported a strong third quarter with a 42% increase in total revenue, reaching $139 million. Crysvita revenue grew by 31% to $98 million, and Dojolvi revenue increased by 29% to $21 million. The company reaffirmed its 2024 total revenue guidance of $530 million to $550 million and highlighted clinical advancements, including Breakthrough Therapy Designation for setrusumab.

Ultragenyx reported a strong second quarter in 2024, with total revenue reaching $147 million, a 36% increase compared to the same period in 2023. The company raised its total revenue guidance for 2024 to $530 million to $550 million. Positive data was reported from Phase 1/2, Phase 2/3, and Phase 3 studies.

Ultragenyx reported $109 million in total revenue for the first quarter of 2024, representing 8% growth compared to the same period in 2023. Crysvita revenue was $83 million, a 9% increase year-over-year, while Dojolvi revenue was $16 million, a 14% increase year-over-year. The company reaffirmed its full-year 2024 revenue guidance.

Ultragenyx reported a 23% increase in total revenue for Q4 2023, reaching $127 million. The company saw growth in Crysvita and Dojolvi sales. They are focused on advancing their Phase 3 programs and executing commercial product launches.

Ultragenyx reported $98.1 million in total revenue for the third quarter 2023, representing 8% growth compared to the third quarter 2022. The company reaffirmed its 2023 expected total revenue guidance between $425 million to $450 million.

Ultragenyx reported a total revenue of $108.3 million for the second quarter of 2023, representing a 21% increase compared to the second quarter of 2022. Crysvita revenue in North America grew by 19% to $61.3 million. The company reaffirmed its 2023 total revenue guidance between $425 million and $450 million.

Ultragenyx reported a 26% increase in total revenue for Q1 2023, driven by Crysvita and Dojolvi. The company is progressing with clinical programs, including UX143 and GTX-102, and reaffirms its 2023 revenue guidance.

Ultragenyx reported Q4 2022 total revenue of $103.3 million. The company reaffirmed its 2023 financial guidance, expecting total revenue between $425 million and $450 million and net cash used in operations to be less than $400 million.

Ultragenyx reported a total revenue of $90.7 million for Q3 2022, with Crysvita revenue in Ultragenyx territories reaching $64.5 million. The company reaffirmed its 2022 revenue guidance for Crysvita and Dojolvi. Enrollment completion of DTX401 Phase 3, UX143 Phase 2, and GTX-102 dose escalation cohorts is anticipated around the end of the year.

Ultragenyx reported second quarter revenue of $89.3 million, including $64.0 million from Crysvita and $13.5 million from Dojolvi. They completed the sale of a capped 30% royalty interest on future Crysvita sales for $500 million and acquired GeneTx. The company reaffirmed its 2022 revenue guidance for Crysvita and Dojolvi.

Ultragenyx reported a total revenue of $79.9 million for the first quarter of 2022. The company reaffirmed its 2022 revenue guidance for Crysvita and Dojolvi.

Ultragenyx reported a total revenue of $83.4 million for Q4 2021. The company made significant progress across its early and late-stage clinical pipeline and is preparing for the launch of Evkeeza in Europe.

Ultragenyx reported third quarter 2021 financial results, with total revenue of $81.6 million. Crysvita revenue in Ultragenyx territories increased 35% compared to the third quarter of 2020. The company is preparing to initiate four additional studies across multiple modalities.

Ultragenyx reported a total revenue of $87.0 million for the second quarter of 2021, which includes $44.7 million from Crysvita. The company reaffirmed its 2021 guidance for Crysvita revenue in Ultragenyx territories to be between $180 million and $190 million.

Ultragenyx reported a total revenue of $99.4 million for the first quarter of 2021, with Crysvita revenue reaching $42.1 million. The company reaffirmed its 2021 Crysvita revenue guidance of $180 million to $190 million. Dojolvi launch continues with approximately 180 patients on reimbursed commercial therapy in the United States.

Ultragenyx reported total revenue of $91.5 million for the fourth quarter of 2020. The company had a net loss of $24.0 million, or $0.37 per share. They reaffirmed the 2021 guidance range for Crysvita of $180 million to $190 million.

Ultragenyx reported Q3 2020 total revenue of $81.5 million, driven by Crysvita revenue of $37.3 million. The company has increased the lower end of Crysvita guidance range; updated full year range is $130 million to $140 million. Dojolvi launch is off to a strong start.

Ultragenyx reported a total revenue of $61.7 million for the second quarter of 2020, including Crysvita revenue in Ultragenyx territories of $32.4 million. The company also had two FDA approvals in the second quarter and maintained its full-year 2020 guidance.

Ultragenyx reported first quarter 2020 financial results, with total revenue of $36.3 million. The company maintains full year 2020 guidance based on COVID-19 impact to date. The FDA reviews for Crysvita for TIO and UX007 for LC-FAOD are on track to be completed in the coming months.

Ultragenyx reported total revenue of $35.6 million for the fourth quarter of 2019. The company's net loss for the quarter was $93.8 million, or $1.62 per share.